The findings indicated that CSI may augment the antitumor efficacy of erlotinib in tumor-bearing mice by inhibiting KRAS and p-ERK1/2, highlighting the potential of this combination therapy for PDAC management. This evidence concerns the gene KRAS and neoplasm.